awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q47763039-65048FE0-D547-4002-A2C9-5C3A576C99E1
Q47763039-65048FE0-D547-4002-A2C9-5C3A576C99E1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47763039-65048FE0-D547-4002-A2C9-5C3A576C99E1
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
P2860
Q47763039-65048FE0-D547-4002-A2C9-5C3A576C99E1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47763039-65048FE0-D547-4002-A2C9-5C3A576C99E1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1158e83dac9450b684e5d051de39d5d6b18f7e67
P2860
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study